{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:31:27Z","timestamp":1794083487204,"version":"4.8.0"},"reference-count":317,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["lzujbky-2023-ey15"],"award-info":[{"award-number":["lzujbky-2023-ey15"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002782","name":"CURE Childhood Cancer Association","doi-asserted-by":"publisher","award":["LZU-JZH2635"],"award-info":[{"award-number":["LZU-JZH2635"]}],"id":[{"id":"10.13039\/100002782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002039","name":"CURE Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014554","name":"Hui-Chun Chin and Tsung-Dao Lee Chinese Undergraduate Research Endowment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003779"],"award-info":[{"award-number":["82003779"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.pharmthera.2024.108593","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T12:22:50Z","timestamp":1706790170000},"page":"108593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Berberine prevents NAFLD and HCC by modulating metabolic disorders"],"prefix":"10.1016","volume":"254","author":[{"given":"Xinyue","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2024.108593_bb0005","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.biopha.2018.08.104","article-title":"Herbal management of hepatocellular carcinoma through cutting the pathways of the common risk factors","volume":"107","author":"Abdel-Hamid","year":"2018","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0010","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1161\/01.ATV.0000181761.16341.2b","article-title":"Extracellular Signal-Regulated Kinase\u2013Dependent Stabilization of Hepatic Low-Density Lipoprotein Receptor mRNA by Herbal Medicine Berberine","volume":"25","author":"Abidi","year":"2005","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2036.2005.02601.x","article-title":"Review article: role of oxidative stress in the progression of non-alcoholic steatosis","volume":"22","author":"Albano","year":"2005","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5604\/16652681.1226814","article-title":"Management Strategies for Liver Fibrosis","volume":"16","author":"Altamirano-Barrera","year":"2017","journal-title":"Annals of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0025","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0030","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2169\/internalmedicine.56.8187","article-title":"A Customized Online Nutrition Guidance System Is Effective for Treating Patients with Nonalcoholic Fatty Liver Disease by Supporting Continuity of Diet Therapy at Home: A Pilot Study","volume":"56","author":"Aoyama","year":"2017","journal-title":"Internal Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10050642","article-title":"Oxidative Stress in Cancer Cell Metabolism","volume":"10","author":"Arfin","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0040","doi-asserted-by":"crossref","first-page":"727","DOI":"10.20960\/nh.723","article-title":"Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update","volume":"34","author":"Assun\u00e7\u00e3o","year":"2017","journal-title":"Nutricion Hospitalaria"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0045","doi-asserted-by":"crossref","first-page":"15718","DOI":"10.1073\/pnas.0407076101","article-title":"The gut microbiota as an environmental factor that regulates fat storage","volume":"101","author":"B\u00e4ckhed","year":"2004","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0050","doi-asserted-by":"crossref","first-page":"18769","DOI":"10.1074\/jbc.M112.365544","article-title":"Liver-specific p70 S6 kinase depletion protects against hepatic steatosis and systemic insulin resistance","volume":"287","author":"Bae","year":"2012","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0055","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.2741\/1683","article-title":"Uncoupling protein-2 and non-alcoholic fatty liver disease","volume":"10","author":"Baffy","year":"2005","journal-title":"Frontiers in Bioscience-Landmark"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0060","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jhep.2011.10.027","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace","volume":"56","author":"Baffy","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118479","article-title":"Berberine hydrochloride inhibits inflammation and fibrosis after canalicular laceration repair in rabbits","volume":"261","author":"Bai","year":"2020","journal-title":"Life Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108593_bb0070","first-page":"1215","article-title":"Clinical observation on berberine treating non-alcoholic fatty liver disease","volume":"38","author":"Bai","year":"2009","journal-title":"Chongqing Med"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0075","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.molonc.2013.01.005","article-title":"Mouse models for liver cancer","volume":"7","author":"Bakiri","year":"2013","journal-title":"Molecular Oncology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: a review","volume":"3","author":"Balogh","year":"2016","journal-title":"Journal of Hepatocellular Carcinoma"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0085","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1002\/ptr.7181","article-title":"Molecular updates on berberine in liver diseases: Bench to bedside","volume":"35","author":"Bansod","year":"2021","journal-title":"Phytotherapy Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0090","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases","volume":"56","author":"Bechmann","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0100","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s001250051481","article-title":"Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes","volume":"43","author":"Bernard","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11695-016-2440-5","article-title":"Pediatric Nonalcoholic Fatty Liver Disease: the Rise of a Lethal Disease Among Mexican American Hispanic Children","volume":"27","author":"Betancourt-Garcia","year":"2017","journal-title":"Obesity Surgery"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0110","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1053\/j.gastro.2016.02.073","article-title":"Changes in the intestinal microbiome and alcoholic and nonalcoholic liver diseases: causes or effects?","volume":"150","author":"Betrapally","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0115","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ccell.2017.08.010","article-title":"A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development","volume":"32","author":"Boege","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.redox.2018.01.009","article-title":"Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches","volume":"15","author":"Borrelli","year":"2018","journal-title":"Redox Biology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0125","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The Severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0130","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3748\/wjg.v18.i8.727","article-title":"Role of cytokines and chemokines in non-alcoholic fatty liver disease","volume":"18","author":"Braunersreuther","year":"2012","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0135","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism-Clinical and Experimental"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0140","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0145","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.2174\/0929867323666160411143314","article-title":"Berberine: new insights from pharmacological aspects to clinical evidences in the management of metabolic disorders","volume":"23","author":"Caliceti","year":"2016","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0150","first-page":"4885","article-title":"Clinical observation on the Berberine plus metformin in treatment of type 2 diabetes complicated by nonalcoholic fatty liver disease","volume":"39","author":"Cao","year":"2012","journal-title":"Mod. Prev. Med"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0155","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterology Clinics of North America"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0160","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.biopha.2018.04.052","article-title":"Coptisine from exerts an anti-cancer effect on hepatocellular carcinoma by up-regulating miR-122","volume":"103","author":"Chai","year":"2018","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0165","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0170","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12967-016-0982-x","article-title":"Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease","volume":"14","author":"Chang","year":"2016","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0175","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1194\/jlr.M001958","article-title":"Berberine reduces methylation of the promoter and alleviates fatty liver induced by a high-fat diet in rats","volume":"51","author":"Chang","year":"2010","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0180","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3389\/fphar.2019.01504","article-title":"Microarray expression profiling and raman spectroscopy reveal anti-fatty liver action of berberine in a diet-induced larval zebrafish model","volume":"10","author":"Chen","year":"2020","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0185","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.7150\/ijbs.47143","article-title":"Kupffer cells in non-alcoholic fatty liver disease: friend or foe?","volume":"16","author":"Chen","year":"2020","journal-title":"International Journal of Biological Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0190","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12967-014-0326-7","article-title":"Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE mice","volume":"12","author":"Chen","year":"2014","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0195","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1208\/s12249-011-9632-z","article-title":"Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats","volume":"12","author":"Chen","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0200","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.3892\/mmr.2016.5017","article-title":"Protective effect of berberine on doxorubicin-induced acute hepatorenal toxicity in rats","volume":"13","author":"Chen","year":"2016","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0205","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12951-021-00979-1","article-title":"Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice","volume":"19","author":"Chen","year":"2021","journal-title":"Journal of Nanobiotechnology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2011\/519371","article-title":"Berberine Improves Glucose Homeostasis in Streptozotocin-Induced Diabetic Rats in Association with Multiple Factors of Insulin Resistance","volume":"2011","author":"Chen","year":"2011","journal-title":"ISRN Endocrinology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0215","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jpha.2021.10.003","article-title":"Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine","volume":"12","author":"Cheng","year":"2022","journal-title":"Journal of Pharmaceutical Analysis"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.livres.2017.05.001","article-title":"Bile acid metabolism and signaling in liver disease and therapy","volume":"1","author":"Chiang","year":"2017","journal-title":"Liver Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12935-017-0429-3","article-title":"Berberine regulates the protein expression of multiple tumorigenesis-related genes in hepatocellular carcinoma cell lines","volume":"17","author":"Chuang","year":"2017","journal-title":"Cancer Cell International"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0230","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3390\/nu13041281","article-title":"The combination of berberine, tocotrienols and coffee extracts improves metabolic profile and liver steatosis by the modulation of gut microbiota and hepatic miR-122 and miR-34a expression in mice","volume":"13","author":"Cossiga","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodres.2021.110318","article-title":"Moringa oleifera leaves alleviated inflammation through downregulation of IL-2, IL-6, and TNF-\u03b1 in a colitis-associated colorectal cancer model","volume":"144","author":"Cuellar-N\u00fa\u00f1ez","year":"2021","journal-title":"Food Research International"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0240","doi-asserted-by":"crossref","first-page":"20108","DOI":"10.1074\/jbc.M314219200","article-title":"PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress","volume":"279","author":"Cullinan","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0245","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ptr.6267","article-title":"Synergistic effect of berberine and HMQ1611 impairs cell proliferation and migration by regulating Wnt signaling pathway in hepatocellular carcinoma","volume":"33","author":"Dai","year":"2019","journal-title":"Phytotherapy Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1872-034X.2007.00215.x","article-title":"Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis","volume":"38","author":"De Oliveira","year":"2007","journal-title":"Hepatology Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0255","first-page":"2091","article-title":"Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2\/ARE signalling pathway","volume":"17","author":"Deng","year":"2019","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0260","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature10189","article-title":"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis","volume":"475","author":"DeNicola","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0265","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/DMSO.S33718","article-title":"Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control","volume":"5","author":"Di Pierro Francesco","year":"2012","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0270","doi-asserted-by":"crossref","first-page":"2958920","DOI":"10.1155\/2019\/2958920","article-title":"The Intervention Effect of Traditional Chinese Medicine on the Intestinal Flora and Its Metabolites in Glycolipid Metabolic Disorders","volume":"2019","author":"Di","year":"2019","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0275","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tox.2010.11.005","article-title":"Hepatoprotective activity of berberine is mediated by inhibition of TNF-\u03b1, COX-2, and iNOS expression in CCl4-intoxicated mice","volume":"280","author":"Domitrovi\u0107","year":"2011","journal-title":"Toxicology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0280","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","author":"Dyson","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0285","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"EASL, EASD, & EASO","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0290","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1097\/MEG.0000000000002140","article-title":"Gut microbiota in nonalcoholic fatty liver diseases with and without type-2 diabetes mellitus","volume":"33","author":"Ebrahimzadeh Leylabadlo","year":"2021","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0295","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0300","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0305","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0310","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.20283","article-title":"Free fatty acids promote hepatic lipotoxicity by stimulating TNF-\u03b1 expression via a lysosomal pathway","volume":"40","author":"Feldstein","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0315","doi-asserted-by":"crossref","first-page":"12155","DOI":"10.1038\/srep12155","article-title":"Transforming berberine into its intestine-absorbable form by the gut microbiota","volume":"5","author":"Feng","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0320","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.biopha.2018.01.071","article-title":"Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin","volume":"99","author":"Feng","year":"2018","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0325","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.7150\/thno.30787","article-title":"Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics","volume":"9","author":"Feng","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0330","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/jmcb\/mjq040","article-title":"Tumor suppressor p53 meets microRNAs","volume":"3","author":"Feng","year":"2011","journal-title":"Journal of Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0335","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4254\/wjh.v2.i4.139","article-title":"Combination drug treatment in patients with non-alcoholic fatty liver disease","volume":"2","author":"Filippatos","year":"2010","journal-title":"World Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0340","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0345","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/nu5051544","article-title":"Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease","volume":"5","author":"Gaggini","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0350","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/hep.21631","article-title":"Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH?","volume":"45","author":"Gambino","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0355","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/gutjnl-2020-323202","article-title":"From the origin of NASH to the future of metabolic fatty liver disease","volume":"70","author":"Geier","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0360","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/00325481.2022.2063568","article-title":"Effect of berberine and bicyclol on Chinese patients with nonalcoholic fatty liver disease: a retrospective study","volume":"134","author":"Geng","year":"2022","journal-title":"Postgraduate Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0365","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/apt.12038","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study","volume":"36","author":"Gerber","year":"2012","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0370","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/hep.26095","article-title":"MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?","volume":"57","author":"Giordano","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089919","article-title":"Approaches to Improve the Oral Bioavailability and Effects of Novel Anticancer Drugs Berberine and Betulinic Acid","volume":"9","author":"Godugu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0380","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbadis.2011.10.008","article-title":"Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis","volume":"1822","author":"Gomes","year":"2012","journal-title":"Biochimica et Biophysica Acta-Molecular Basis of Disease"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.722360","article-title":"Berberine Alleviates Insulin Resistance and Inflammation Inhibiting the LTB4-BLT1 Axis","volume":"12","author":"Gong","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116927","article-title":"Chinese herbal medicines: The modulator of nonalcoholic fatty liver disease targeting oxidative stress","volume":"318","author":"Gong","year":"2024","journal-title":"Journal of Ethnopharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0395","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.suronc.2016.03.002","article-title":"Hepatocellular carcinoma: From diagnosis to treatment","volume":"25","author":"Grandhi","year":"2016","journal-title":"Surgical Oncology-Oxford"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225844","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: from epidemiology to diagnostic approach","volume":"13","author":"Grgurevic","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0405","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nature10887","article-title":"Modular regulatory principles of large non-coding RNAs","volume":"482","author":"Guttman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0410","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-physiol-021115-105331","article-title":"Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease","volume":"78","author":"Haas","year":"2016","journal-title":"Annual Review of Physiology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104722","article-title":"Berberine pharmacology and the gut microbiota: A hidden therapeutic link","volume":"155","author":"Habtemariam","year":"2020","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0420","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.molcel.2011.01.002","article-title":"Sirt3 Promotes the Urea Cycle and Fatty Acid Oxidation during Dietary Restriction","volume":"41","author":"Hallows","year":"2011","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0425","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/flgastro-2014-100432","article-title":"Non-alcoholic fatty liver disease is associated with higher levels ofobjectivelymeasured sedentary behaviour and lower levels of physical activity than matched healthy controls","volume":"6","author":"Hallsworth","year":"2015","journal-title":"Frontline Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0430","doi-asserted-by":"crossref","first-page":"16220","DOI":"10.1038\/s41598-018-34474-9","article-title":"Overexpression of CD98 in intestinal epithelium dysregulates miRNAs and their targeted proteins along the ileal villus-crypt axis","volume":"8","author":"Han","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0435","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2337\/diabetes.53.10.2623","article-title":"Elevations in Markers of Liver Injury and Risk of Type 2 Diabetes","volume":"53","author":"Hanley","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0440","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.bcp.2008.03.004","article-title":"Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases","volume":"75","author":"Hardwick","year":"2008","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0445","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/B978-0-12-404717-4.00005-6","article-title":"Eicosanoids in metabolic syndrome","volume":"66","author":"Hardwick","year":"2013","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0450","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0455","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/17474124.2018.1512853","article-title":"Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future?","volume":"12","author":"Hatton","year":"2018","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0460","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.bbadis.2016.06.006","article-title":"alkaloids alleviate hyperlipidemia in B6 mice by modulating gut microbiota and bile acid pathways","volume":"1862","author":"He","year":"2016","journal-title":"Biochimica et Biophysica Acta-Molecular Basis of Disease"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0465","doi-asserted-by":"crossref","first-page":"37657","DOI":"10.18632\/oncotarget.17489","article-title":"Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0470","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nature Reviews Genetics"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0475","doi-asserted-by":"crossref","first-page":"9655","DOI":"10.1002\/jcb.27392","article-title":"Berberine: A potential adjunct for the treatment of gastrointestinal cancers?","volume":"119","author":"Hesari","year":"2018","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0480","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature08778","article-title":"SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation","volume":"464","author":"Hirschey","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0485","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000449336","article-title":"Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)","volume":"5","author":"Ho","year":"2016","journal-title":"Liver Cancer"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0490","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2020","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0495","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis - aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0500","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ptr.2399","article-title":"Pharmacological and therapeutic effects of and its active constituent, berberine","volume":"22","author":"Imanshahidi","year":"2008","journal-title":"Phytotherapy Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0505","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ptr.6252","article-title":"Berberine and barberry (Berberis vulgaris): A clinical review","volume":"33","author":"Imenshahidi","year":"2019","journal-title":"Phytotherapy Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172900","article-title":"New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans","volume":"12","author":"Inzaugarat","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0515","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2007.06.001","article-title":"Endogenous bile acids as carcinogens","volume":"47","author":"Jansen","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0520","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.metabol.2007.04.006","article-title":"Reduced capacity for fatty acid oxidation in rats with inherited susceptibility to diet-induced obesity","volume":"56","author":"Ji","year":"2007","journal-title":"Metabolism-Clinical and Experimental"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0525","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3892\/or.2016.5327","article-title":"Berberine affects osteosarcoma via downregulating the caspase-1\/IL-1\u03b2 signaling axis","volume":"37","author":"Jin","year":"2017","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0530","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.3760\/cma.j.issn.0366-6999.20130940","article-title":"Uncoupling protein and nonalcoholic fatty liver disease","volume":"126","author":"Jin","year":"2013","journal-title":"Chinese Medical Journal"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0535","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/liv.13613","article-title":"More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma","volume":"38","author":"Jun","year":"2018","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0540","first-page":"49","article-title":"Consequences of Heteromeric Interactions among Helix-Loop-Helix Proteins","volume":"4","author":"Kadesch","year":"1993","journal-title":"Cell Growth and Differentiation"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0545","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1753425908095130","article-title":"Lipopolysaccharide associates with pro-atherogenic lipoproteins in periodontitis patients","volume":"14","author":"Kallio","year":"2008","journal-title":"Innate Immunity"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0550","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.fct.2010.01.033","article-title":"Acute toxicity of berberine and its correlation with the blood concentration in mice","volume":"48","author":"Kheir","year":"2010","journal-title":"Food and Chemical Toxicology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0555","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3389\/fendo.2018.00485","article-title":"Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches","volume":"9","author":"Kim","year":"2018","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0560","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.3390\/ijms21155502","article-title":"Induction of Apoptosis by Coptisine in Hep3B Hepatocellular Carcinoma Cells through Activation of the ROS-Mediated JNK Signaling Pathway","volume":"21","author":"Kim","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0565","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm1135","article-title":"Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins","volume":"10","author":"Kong","year":"2004","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0570","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.metabol.2008.08.013","article-title":"Berberine reduces insulin resistance through protein kinase C\u2013dependent up-regulation of insulin receptor expression","volume":"58","author":"Kong","year":"2009","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0575","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejphar.2015.05.068","article-title":"Current knowledge and pharmacological profile of berberine: An update","volume":"761","author":"Kumar","year":"2015","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0580","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3892\/ijmm.2012.1049","article-title":"Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis","volume":"30","author":"Kuo","year":"2012","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0585","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","article-title":"Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension","volume":"161","author":"Lan","year":"2015","journal-title":"Journal of Ethnopharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0590","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1006\/bbrc.1997.6852","article-title":"Kupffer cells are a dominant site of uncoupling protein 2 expression in rat liver","volume":"235","author":"Larrouy","year":"1997","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0595","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and regulation of the inflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0600","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","article-title":"Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279013 individuals","volume":"39","author":"Lauridsen","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0605","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents The TONIC Randomized Controlled Trial","volume":"305","author":"Lavine","year":"2011","journal-title":"Jama-Journal of the American Medical Association"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0610","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1126\/science.1158042","article-title":"Regulation of hepatic lipogenesis by the transcription factor XBP1","volume":"320","author":"Lee","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0615","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.livres.2018.12.001","article-title":"Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2","volume":"2","author":"Lee","year":"2018","journal-title":"Liver Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0620","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.2337\/db06-0006","article-title":"Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states","volume":"55","author":"Lee","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0625","first-page":"496","article-title":"Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion","volume":"25","author":"Leng","year":"2004","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0630","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3748\/wjg.v21.i4.1189","article-title":"Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease","volume":"21","author":"Leung","year":"2015","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0635","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0009922808321678","article-title":"Age- and Ethnic-Specific Elevation of ALT Among Obese Children at Risk for Nonalcoholic Steatohepatitis (NASH): Implications for Screening","volume":"48","author":"Leung","year":"2008","journal-title":"Clinical Pediatrics"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104603","article-title":"Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-\u03baB pathway","volume":"152","author":"Li","year":"2020","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0645","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2018.02.035","article-title":"Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway","volume":"825","author":"Li","year":"2018","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153631","article-title":"Dihydroberberine, an isoquinoline alkaloid, exhibits protective effect against dextran sulfate sodium-induced ulcerative colitis in mice","volume":"90","author":"Li","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0655","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.phymed.2018.09.228","article-title":"Comparison of anti-inflammatory effects of berberine, and its natural oxidative and reduced derivatives from Rhizoma Coptidis and","volume":"52","author":"Li","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0660","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.phymed.2018.09.228","article-title":"Comparison of anti-inflammatory effects of berberine, and its natural oxidative and reduced derivatives from Rhizoma Coptidis in vitro and in vivo","volume":"52","author":"Li","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0665","first-page":"1598","article-title":"Up-regulation of microRNA-367 promotes liver steatosis through repressing TBL1 in obese mice","volume":"21","author":"Li","year":"2017","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0670","first-page":"363","article-title":"Observation of the clinical effects of berberine combined with Yi-gan-Ling in the treatment of metabolize syndrome with nonalcoholic steatohepatitis","volume":"19","author":"Li","year":"2015","journal-title":"Anhui Med. Pharm. J"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0675","article-title":"Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease","volume":"13","author":"Li","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0680","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/CIRCULATIONAHA.115.019645","article-title":"Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Mice","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0685","doi-asserted-by":"crossref","first-page":"16422","DOI":"10.1038\/srep16422","article-title":"miR-23a binds to p53 and enhances its association with miR-128 promoter","volume":"5","author":"Li","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153550","article-title":"Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats","volume":"85","author":"Li","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0695","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile Acid Signaling in Metabolic Disease and Drug Therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0700","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.febslet.2011.04.051","article-title":"Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes","volume":"585","author":"Li","year":"2011","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0705","article-title":"Antioxidant and Anti-Inflammatory Activities of Berberine in the Treatment of Diabetes Mellitus","volume":"2014","author":"Li","year":"2014","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0710","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/omi.2019.0035","article-title":"Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis","volume":"23","author":"Lin","year":"2019","journal-title":"Omics-a Journal of Integrative Biology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0715","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0720","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jep.2017.07.023","article-title":"Computational and experimental prediction of molecules involved in the anti-melanoma action of berberine","volume":"208","author":"Liu","year":"2017","journal-title":"Journal of Ethnopharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0725","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.fitote.2016.02.001","article-title":"Research progress on berberine with a special focus on its oral bioavailability","volume":"109","author":"Liu","year":"2016","journal-title":"Fitoterapia"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0730","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1055\/s-0043-125066","article-title":"Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway","volume":"126","author":"Liu","year":"2018","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108593_bb0735","first-page":"2519","article-title":"Treatment of 34 cases of non-alcoholic fatty liver with berberine hydrochloride","volume":"22","author":"Liu","year":"2006","journal-title":"JK Practitioner"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0740","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2222.2012.03978.x","article-title":"High expression of CD98 alters epithelial barrier functions to promote induction of airway allergy","volume":"42","author":"Liu","year":"2012","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0745","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1124\/dmd.110.033936","article-title":"Extensive Intestinal First-Pass Elimination and Predominant Hepatic Distribution of Berberine Explain Its Low Plasma Levels in Rats","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0750","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/jps.21721","article-title":"Oxidative Demethylenation and Subsequent Glucuronidation Are the Major Metabolic Pathways of Berberine in Rats","volume":"98","author":"Liu","year":"2009","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0755","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075628","article-title":"MicroRNA-21-3p, a Berberine-Induced miRNA, Directly Down-Regulates Human Methionine Adenosyltransferases 2A and 2B and Inhibits Hepatoma Cell Growth","volume":"8","author":"Lo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0760","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1677\/JOE-08-0419","article-title":"Berberine promotes glucagon-like peptide-1 (7\u201336) amide secretion in streptozotocin-induced diabetic rats","volume":"200","author":"Lu","year":"2009","journal-title":"Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0765","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12865-020-00358-9","article-title":"Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway","volume":"21","author":"Lu","year":"2020","journal-title":"BMC Immunology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0770","first-page":"2668","article-title":"Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice","volume":"11","author":"Luo","year":"2019","journal-title":"American Journal of Translational Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0775","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3920\/BM2010.0030","article-title":"Intestinal microbiota and overweight","volume":"1","author":"Lyra","year":"2010","journal-title":"Beneficial Microbes"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0780","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1002\/jps.23718","article-title":"Excretion of Berberine and Its Metabolites in Oral Administration in Rats","volume":"102","author":"Ma","year":"2013","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0785","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/antiox11010091","article-title":"Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease","volume":"11","author":"Ma","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0790","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/00365520701559003","article-title":"Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet","volume":"43","author":"Machado","year":"2009","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0795","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fphar.2020.00185","article-title":"Berberine Inhibits Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome Activation and Pyroptosis in Nonalcoholic Steatohepatitis the ROS\/TXNIP Axis","volume":"11","author":"Mai","year":"2020","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0800","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","article-title":"Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease","volume":"52","author":"Makri","year":"2021","journal-title":"Archives of Medical Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0805","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2010.11.005","article-title":"Endoplasmic reticulum stress in liver disease","volume":"54","author":"Malhi","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0810","doi-asserted-by":"crossref","first-page":"18525","DOI":"10.1073\/pnas.0809677105","article-title":"Antioxidants reduce endoplasmic reticulum stress and improve protein secretion","volume":"105","author":"Malhotra","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0815","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s12325-011-0082-5","article-title":"Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients","volume":"28","author":"Marazzi","year":"2011","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0820","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0825","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.32427","article-title":"Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles","volume":"76","author":"Mart\u00ednez-Arranz","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0830","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2014.08.007","article-title":"Endoplasmic Reticulum Stress: At the Crossroads of Inflammation and Metabolism in Hepatocellular Carcinoma Development","volume":"26","author":"Maurel","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0835","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3390\/nu9121348","article-title":"Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance","volume":"9","author":"McNabney","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0840","doi-asserted-by":"crossref","first-page":"39282","DOI":"10.1074\/jbc.M105077200","article-title":"CD98-mediated Links between Amino Acid Transport and \u03b21 Integrin Distribution in Polarized Columnar Epithelia","volume":"276","author":"Merlin","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0845","first-page":"S30","article-title":"Genetic influences in nonalcoholic fatty liver disease","volume":"40","author":"Merriman","year":"2006","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0850","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3748\/wjg.v21.i6.1691","article-title":"Gut microbiota and liver diseases","volume":"21","author":"Minemura","year":"2015","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0855","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.molmed.2018.03.005","article-title":"IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies","volume":"24","author":"Mirea","year":"2018","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0860","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0865","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.biopha.2016.12.023","article-title":"Regulation of miRNAs by herbal medicine: An emerging field in cancer therapies","volume":"86","author":"Mohammadi","year":"2017","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0870","first-page":"538","article-title":"and its constituent berberine as antidotes and protective agents against natural or chemical toxicities","volume":"20","author":"Mohammadzadeh","year":"2017","journal-title":"Iranian Journal of Basic Medical Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0875","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2004.01.028","article-title":"Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis","volume":"40","author":"Namikawa","year":"2004","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0880","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0002-9440(10)63182-3","article-title":"Epithelia under metabolic stress perceive commensal bacteria as a threat","volume":"164","author":"Nazli","year":"2004","journal-title":"American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0885","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/jgh.13318","article-title":"Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease","volume":"31","author":"Nishida","year":"2016","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0890","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/j.gastro.2016.03.009","article-title":"Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease","volume":"150","author":"Nobili","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0895","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2009.05.017","article-title":"Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease","volume":"51","author":"Nozaki","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0900","first-page":"26","article-title":"Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease","volume":"55","author":"Ore","year":"2019","journal-title":"Medicina-Lithuania"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114841","article-title":"CYP4V2 fatty acid omega hydroxylase, a druggable target for the treatment of metabolic associated fatty liver disease (MAFLD)","volume":"195","author":"Osborne","year":"2022","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0910","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1517\/13543784.13.12.1555","article-title":"Systemic therapies for hepatocellular carcinoma","volume":"13","author":"Palmer","year":"2005","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0915","first-page":"911","article-title":"Inhibitory action of berberine on glucose absorption","volume":"38","author":"Pan","year":"2003","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0920","doi-asserted-by":"crossref","first-page":"794","DOI":"10.7150\/ijbs.18969","article-title":"Berberine Reverses Hypoxia-induced Chemoresistance in Breast Cancer through the Inhibition of AMPK- HIF-1\u03b1","volume":"13","author":"Pan","year":"2017","journal-title":"International Journal of Biological Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0925","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/905749","article-title":"Application of Berberine on Treating Type 2 Diabetes Mellitus","volume":"2015","author":"Pang","year":"2015","journal-title":"International Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0930","doi-asserted-by":"crossref","first-page":"31423","DOI":"10.1074\/jbc.M204080200","article-title":"Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin","volume":"277","author":"Park","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0935","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mi.2014.44","article-title":"Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway","volume":"8","author":"Park","year":"2015","journal-title":"Mucosal Immunology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0940","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/met.2012.0183","article-title":"Effect of Berberine Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion","volume":"11","author":"P\u00e9rez-Rubio","year":"2013","journal-title":"Metabolic Syndrome and Related Disorders"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0945","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0950","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bbabio.2007.07.011","article-title":"Mitochondrial dysfunction in rat with nonalcoholic fatty liver Involvement of complex I, reactive oxygen species and cardiolipin","volume":"1767","author":"Petrosillo","year":"2007","journal-title":"Biochimica et Biophysica Acta-Bioenergetics"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0955","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nm.4236","article-title":"A purified membrane protein from or the pasteurized bacterium improves metabolism in obese and diabetic mice","volume":"23","author":"Plovier","year":"2017","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0960","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2011.04.008","article-title":"Targeted therapy of liver fibrosis\/cirrhosis and its complications","volume":"55","author":"Poelstra","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0965","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metabolism-Clinical and Experimental"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0970","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.freeradbiomed.2016.11.037","article-title":"Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation","volume":"102","author":"Porras","year":"2017","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0975","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice","volume":"118","author":"Postic","year":"2008","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0980","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1053\/j.gastro.2007.10.039","article-title":"Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease","volume":"134","author":"Puri","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0985","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1002\/j.1536-4801.2016.tb00027.x","article-title":"Pediatric NAFLD: the Future role of Patient-Tailored Probiotics Therapy","volume":"63","author":"Putignani","year":"2016","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0990","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A human gut microbial gene catalogue established by metagenomic sequencing","volume":"464","author":"Qin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2024.108593_bb0995","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1124\/dmd.108.021659","article-title":"Isolation and Identification of Urinary Metabolites of Berberine in Rats and Humans","volume":"36","author":"Qiu","year":"2008","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1000","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.cmet.2010.11.015","article-title":"Calorie Restriction Reduces Oxidative Stress by SIRT3-Mediated SOD2 Activation","volume":"12","author":"Qiu","year":"2010","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1005","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/nu11030541","article-title":"Dietary Polyphenols Protect Against Oleic Acid-Induced Steatosis in an in Vitro Model of NAFLD by Modulating Lipid Metabolism and Improving Mitochondrial Function","volume":"11","author":"Rafiei","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/j.gastro.2016.06.022","article-title":"Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol","volume":"151","author":"Rahman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1020","doi-asserted-by":"crossref","first-page":"7368","DOI":"10.3390\/molecules26237368","article-title":"Berberine as a Potential Anticancer Agent: A Comprehensive Review","volume":"26","author":"Rauf","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1025","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/gutjnl-2017-315084","article-title":"Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma","volume":"68","author":"Ren","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1035","doi-asserted-by":"crossref","DOI":"10.3390\/biom10121702","article-title":"Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants","volume":"10","author":"Rives","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1040","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/414799a","article-title":"Insulin signalling and the regulation of glucose and lipid metabolism","volume":"414","author":"Saltiel","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1045","doi-asserted-by":"crossref","first-page":"32345","DOI":"10.1074\/jbc.M313478200","article-title":"Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease","volume":"279","author":"Samuel","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1050","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1185\/03007995.2010.506375","article-title":"Population-based risk factors and resource utilization for HCC: US perspective","volume":"26","author":"Sanyal","year":"2010","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.571731","article-title":"Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes","volume":"11","author":"Scheithauer","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2019.08.016","article-title":"Gut microbiome in HCC - Mechanisms, diagnosis and therapy","volume":"72","author":"Schwabe","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0168-8278(02)00073-9","article-title":"In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases","volume":"37","author":"Seki","year":"2002","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3803\/EnM.2013.28.1.41","article-title":"Tumor Necrosis Factor-\u03b1 as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Follow-Up Study","volume":"28","author":"Seo","year":"2013","journal-title":"Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1075","article-title":"Association between Noninvasive Fibrosis Markers and Cardio-Vascular Organ Damage among Adults with Hepatic Steatosis","volume":"9","author":"Sesti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1080","first-page":"662","article-title":"Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries","volume":"15","author":"Seyda Seydel","year":"2016","journal-title":"Annals of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.joim.2021.09.003","article-title":"Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis","volume":"19","author":"Shan","year":"2021","journal-title":"Journal of Integrative Medicine-Jim"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1090","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1210\/jc.2008-1001","article-title":"Endoplasmic Reticulum Stress Markers Are Associated with Obesity in Nondiabetic Subjects","volume":"93","author":"Sharma","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.biopha.2017.09.039","article-title":"The synergy of diammonium glycyrrhizinate remarkably reduces the toxicity of oxymatrine in ICR mice","volume":"97","author":"Shi","year":"2018","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1100","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cmet.2010.11.003","article-title":"SIRT3 Deacetylates Mitochondrial 3-Hydroxy-3-Methylglutaryl CoA Synthase 2 and Regulates Ketone Body Production","volume":"12","author":"Shimazu","year":"2010","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154842","article-title":"Berberine activates PPAR\u03b4 and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma","volume":"115","author":"Shou","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1110","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-3-030-64872-5_18","article-title":"Beneficial Effects of Plant-Derived Natural Products on Non-alcoholic Fatty Liver Disease","volume":"1308","author":"Simental-Mend\u00eda","year":"2021","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1115","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1517\/13543776.2013.746314","article-title":"Berberine and its derivatives: a patent review (2009-2012)","volume":"23","author":"Singh","year":"2013","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1125","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2020.10.015","article-title":"Non-alcoholic fatty liver disease: Not time for an obituary just yet!","volume":"74","author":"Singh","year":"2021","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1130","first-page":"4654","article-title":"Exploring the active mechanism of berberine against HCC by systematic pharmacology and experimental validation","volume":"20","author":"Song","year":"2019","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1135","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1055\/s-0039-1679920","article-title":"Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics","volume":"39","author":"Sookoian","year":"2019","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1140","first-page":"247","article-title":"A Review on Biological and Chemical Diversity in (Berberidaceae)","volume":"14","author":"Srivastava","year":"2015","journal-title":"EXCLI Journal"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1145","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1007\/s10620-007-9810-8","article-title":"Nonalcoholic steatohepatitis (NASH) in OB\/OB mice treated with yo jyo hen shi ko (YHK): Effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP)","volume":"52","author":"Stefano","year":"2007","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1150","doi-asserted-by":"crossref","first-page":"20220648","DOI":"10.1515\/biol-2022-0648","article-title":"Berberine suppressed sarcopenia insulin resistance through SIRT1-mediated mitophagy","volume":"18","author":"Su","year":"2023","journal-title":"Open Life Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1155","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.2147\/DMSO.S313068","article-title":"Berberine Ameliorates Hepatic Insulin Resistance by Regulating microRNA-146b\/SIRT1 Pathway","volume":"14","author":"Sui","year":"2021","journal-title":"Diabetes Metabolic Syndrome and Obesity-Targets and Therapy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1160","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3390\/ijms21061907","article-title":"Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis","volume":"21","author":"Sumida","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1165","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/mol.116.106617","article-title":"Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway","volume":"91","author":"Sun","year":"2017","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1170","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1248\/bpb.32.1533","article-title":"Berberine Inhibits Hepatic Stellate Cell Proliferation and Prevents Experimental Liver Fibrosis","volume":"32","author":"Sun","year":"2009","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1175","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bph.14079","article-title":"Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21","volume":"175","author":"Sun","year":"2018","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1180","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","article-title":"Inflammasome activation and function in liver disease","volume":"12","author":"Szabo","year":"2015","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1185","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105802","article-title":"Dihydroberberine, a hydrogenated derivative of berberine firstly identified in Phellodendri Chinese Cortex, exerts anti-inflammatory effect via dual modulation of NF-\u03baB and MAPK signaling pathways","volume":"75","author":"Tan","year":"2019","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077969","article-title":"Tissue Distribution of Berberine and Its Metabolites after Oral Administration in Rats","volume":"8","author":"Tan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1195","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000282083","article-title":"The Role of Cytokines in Non-Alcoholic Fatty Liver Disease","volume":"28","author":"Tilg","year":"2010","journal-title":"Digestive Diseases"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.bbadis.2014.12.004","article-title":"Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma","volume":"1852","author":"Tsang","year":"2015","journal-title":"Biochimica et Biophysica Acta-Molecular Basis of Disease"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1205","first-page":"863","article-title":"Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy","volume":"18","author":"Tunissiolli","year":"2017","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1210","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1093\/nar\/gkr254","article-title":"Characterization of extracellular circulating microRNA","volume":"39","author":"Turchinovich","year":"2011","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1215","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/db07-1552","article-title":"Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: A mechanism for the action of berberine to activate AMP-Activated protein kinase and improve insulin action","volume":"57","author":"Turner","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1220","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1210\/jc.2006-0587","article-title":"Review: The role of insulin resistance in nonalcoholic fatty liver disease","volume":"91","author":"Utzschneider","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1225","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1230","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMc1006581","article-title":"Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis","volume":"363","author":"Violi","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1235","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.2337\/diabetes.51.6.1889","article-title":"High Alanine Aminotransferase Is Associated With Decreased Hepatic Insulin Sensitivity and Predicts the Development of Type 2 Diabetes","volume":"51","author":"Vozarova","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1240","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1210\/en.2005-0570","article-title":"Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis","volume":"147","author":"Wang","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1245","doi-asserted-by":"crossref","first-page":"10135","DOI":"10.18632\/oncotarget.20807","article-title":"Metformin and berberine, two versatile drugs in treatment of common metabolic diseases","volume":"9","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1250","first-page":"681","article-title":"Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia","volume":"36","author":"Wang","year":"2016","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1255","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.bbagrm.2014.05.027","article-title":"Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma","volume":"1839","author":"Wang","year":"2014","journal-title":"Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1260","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40139-012-0003-6","article-title":"Bile Acid Receptors and Liver Cancer","volume":"1","author":"Wang","year":"2012","journal-title":"Current Pathobiology Reports"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1265","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/ijms17040577","article-title":"Up-Regulation of PAI-1 and Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine","volume":"17","author":"Wang","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1270","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1016\/j.lfs.2005.02.033","article-title":"Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of extract","volume":"77","author":"Wang","year":"2005","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1275","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2147\/CMAR.S242329","article-title":"The anti-cancer mechanisms of berberine: a review","volume":"12","author":"Wang","year":"2020","journal-title":"Cancer Management and Research"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1280","doi-asserted-by":"crossref","first-page":"e0232630","DOI":"10.1371\/journal.pone.0232630","article-title":"Berberine inhibits free fatty acid and LPS-induced inflammation modulating ER stress response in macrophages and hepatocytes","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1285","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cells10020210","article-title":"Berberine prevents disease progression of nonalcoholic steatohepatitis through modulating multiple pathways","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1290","article-title":"Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4\u03b1 miR122 Pathway","volume":"11","author":"Wei","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1295","doi-asserted-by":"crossref","first-page":"3593951","DOI":"10.1155\/2016\/3593951","article-title":"The therapeutic effect of berberine in the treatment of nonalcoholic fatty liver disease: a meta-analysis","volume":"2016","author":"Wei","year":"2016","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1300","doi-asserted-by":"crossref","first-page":"421","DOI":"10.21037\/atm-23-1208","article-title":"Research reporting guidelines for cell lines: more than just a recommendation","volume":"11","author":"Weiskirchen","year":"2023","journal-title":"Annals of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1305","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1101\/gad.1800909","article-title":"Long noncoding RNAs: functional surprises from the RNA world","volume":"23","author":"Wilusz","year":"2009","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1310","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1315","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U. S","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1320","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/stem.2454","article-title":"Concise review: current status and future directions on research related to nonalcoholic fatty liver disease","volume":"35","author":"Wruck","year":"2017","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1325","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112955","article-title":"Berberine reduces hepatic ceramide levels to improve insulin resistance in HFD-fed mice by inhibiting HIF-2\u03b1","volume":"150","author":"Xia","year":"2022","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1330","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s13238-020-00814-7","article-title":"The role of the gut microbiome and its metabolites in metabolic diseases","volume":"12","author":"Wu","year":"2020","journal-title":"Protein & Cell"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1335","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41419-019-1706-y","article-title":"Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans","volume":"10","author":"Wu","year":"2019","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1340","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11655-010-0188-7","article-title":"Advance of Studies on Anti-atherosclerosis Mechanism of Berberine","volume":"16","author":"Wu","year":"2010","journal-title":"Chinese Journal of Integrative Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1345","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-022-01257-8","article-title":"The sirtuin family in health and disease","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1350","first-page":"2905","article-title":"Effect of berberine combined with rosuvastatin in treatment of nonalcoholic fatty liver disease","volume":"26","author":"Wu","year":"2020","journal-title":"Medical Recapitulate"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1355","first-page":"3032","article-title":"Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease","volume":"36","author":"Xie","year":"2011","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1360","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejphar.2011.07.036","article-title":"Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver","volume":"668","author":"Xing","year":"2011","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1365","first-page":"4865","article-title":"Berberine alleviates amyloid \u03b225-35-induced inflammatory response in human neuroblastoma cells by inhibiting proinflammatory factors","volume":"16","author":"Xu","year":"2018","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1370","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.3892\/mmr.2017.6321","article-title":"Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels","volume":"15","author":"Xu","year":"2017","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1375","article-title":"Berberine promotes glucose consumption independently of AMP-activated protein kinase activation","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1380","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1096\/fj.201802316R","article-title":"Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3","volume":"33","author":"Xu","year":"2019","journal-title":"FASEB Journal"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1385","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm788","article-title":"Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase","volume":"8","author":"Yamauchi","year":"2002","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1390","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134172","article-title":"Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease","volume":"10","author":"Yan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1400","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.freeradbiomed.2020.02.029","article-title":"Mitochondrial superoxide\/hydrogen peroxide: An emerging therapeutic target for metabolic diseases","volume":"152","author":"Yan","year":"2020","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1405","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apsb.2019.11.017","article-title":"Herbal drug discovery for the treatment of nonalcoholic fatty liver disease","volume":"10","author":"Yan","year":"2020","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1410","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","article-title":"Hepatocellular carcinoma: a global view","volume":"7","author":"Yang","year":"2010","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1415","doi-asserted-by":"crossref","first-page":"12115","DOI":"10.1039\/D1FO02783B","article-title":"Antiproliferative activity of berberine in HepG2 cells inducing apoptosis and arresting cell cycle","volume":"12","author":"Yang","year":"2021","journal-title":"Food & Function"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1420","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1039\/D1BM01765A","article-title":"An oral pH-activated \u201cnano-bomb\u201d carrier combined with berberine by regulating gene silencing and gut microbiota for site-specific treatment of ulcerative colitis","volume":"10","author":"Yang","year":"2022","journal-title":"Biomaterials Science"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1425","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11655-011-0668-4","article-title":"Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats","volume":"17","author":"Yang","year":"2011","journal-title":"Chinese Journal of Integrative Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1430","article-title":"Berberrubine, a main metabolite of berberine, alleviates non-alcoholic fatty liver disease modulating glucose and lipid metabolism and restoring gut microbiota","volume":"13","author":"Yang","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1435","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/abbi.2000.1829","article-title":"Mitochondrial adaptations to obesity-related oxidant stress","volume":"378","author":"Yang","year":"2000","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1440","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000525582","article-title":"Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: expert recommendations from Hong Kong, Singapore, and Taiwan","volume":"11","author":"Yau","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1445","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2011.06.002","article-title":"Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways","volume":"14","author":"Yecies","year":"2011","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1450","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jep.2012.10.062","article-title":"Safety evaluation of main alkaloids from","volume":"145","author":"Yi","year":"2013","journal-title":"Journal of Ethnopharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1455","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.metabol.2008.01.013","article-title":"Efficacy of berberine in patients with type 2 diabetes mellitus","volume":"57","author":"Yin","year":"2008","journal-title":"Metabolism-Clinical and Experimental"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1460","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1465","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1475","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States From 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1480","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: Implications of a Premature Change in Terminology","volume":"73","author":"Younossi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1485","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.7150\/ijbs.54604","article-title":"Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver","volume":"17","author":"Yu","year":"2021","journal-title":"International Journal of Biological Sciences"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1490","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1475-2867-14-49","article-title":"Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation","volume":"14","author":"Yu","year":"2014","journal-title":"Cancer Cell International"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1495","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12967-015-0383-6","article-title":"Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles","volume":"13","author":"Yuan","year":"2015","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1500","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2174\/1381612822666161010115235","article-title":"Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes","volume":"23","author":"Zabihi","year":"2017","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1505","article-title":"Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4\u03b1 miR122 Pathway","volume":"11","author":"Zang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1510","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/biom12081079","article-title":"Progress in nonalcoholic fatty liver disease: SIRT family regulates mitochondrial biogenesis","volume":"12","author":"Zeng","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1515","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/med.21734","article-title":"Small molecules regulating reactive oxygen species homeostasis for cancer therapy","volume":"41","author":"Zhang","year":"2020","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1520","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1525","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1210\/jc.2007-2404","article-title":"Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine","volume":"93","author":"Zhang","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1530","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11596-019-1997-3","article-title":"Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3\/AMPK\/ACC Pathway","volume":"39","author":"Zhang","year":"2019","journal-title":"Current Medical Science"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1535","doi-asserted-by":"crossref","first-page":"20848","DOI":"10.1038\/srep20848","article-title":"Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress","volume":"6","author":"Zhang","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1540","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1248\/bpb.35.796","article-title":"Protective Effects of Berberine on Doxorubicin-Induced Hepatotoxicity in Mice","volume":"35","author":"Zhao","year":"2012","journal-title":"Biological & Pharmaceutical Bulletin"},{"issue":"14","key":"10.1016\/j.pharmthera.2024.108593_bb1545","first-page":"51","article-title":"Effects of Berberine hydrochloride combined with Metformin in treatment of patients with non-alcoholic fatty liver","volume":"34","author":"Zhao","year":"2022","journal-title":"Medical Journal of Chinese People's Health"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1550","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1875-5364(19)30101-3","article-title":"a promising target for the therapy of metabolic syndrome and related diseases","volume":"17","author":"Zhou","year":"2019","journal-title":"Chinese Journal of Natural Medicines"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1555","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-019-14138-6","article-title":"SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1560","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1248\/bpb.31.1169","article-title":"Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats","volume":"31","author":"Zhou","year":"2008","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173655","article-title":"The pharmacological activity of berberine, a review for liver protection","volume":"890","author":"Zhou","year":"2021","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1570","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/molecules21101336","article-title":"The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease","volume":"21","author":"Zhu","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1575","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","article-title":"Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway","volume":"141","author":"Zhu","year":"2019","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1580","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.bbrc.2017.10.149","article-title":"MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator","volume":"494","author":"Zhuge","year":"2017","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2024.108593_bb1585","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1089\/ars.2013.5538","article-title":"Mitochondrial Dysfunction in Obesity-Associated Nonalcoholic Fatty Liver Disease: The Protective Effects of Pomegranate with Its Active Component Punicalagin","volume":"21","author":"Zou","year":"2014","journal-title":"Antioxidants & Redox Signaling"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824000135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824000135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:35:35Z","timestamp":1759012535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725824000135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":317,"alternative-id":["S0163725824000135"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108593","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Berberine prevents NAFLD and HCC by modulating metabolic disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108593"}}